Gold prices hit record high above $3,600/oz on rate cut bets, haven appeal
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock surged 13% Thursday morning following disappointing clinical trial results from Sanofi’s (NASDAQ:SNY) amlitelimab treatment for atopic dermatitis.
The positive market reaction for Nektar appears linked to competitive positioning for its own atopic dermatitis candidate. Sanofi’s amlitelimab data, while meeting primary and secondary endpoints in its Phase 3 COAST-1 trial, fell below efficacy expectations according to market observers.
This development potentially strengthens the market position of Nektar’s lead drug candidate rezpegaldesleukin (REZPEG), a regulatory T cell stimulator currently in Phase 2b clinical trials for atopic dermatitis and alopecia areata. In June, Nektar announced that its REZOLVE-AD Phase 2b study of rezpegaldesleukin met both primary and key secondary endpoints in patients with moderate-to-severe atopic dermatitis.
Nektar Therapeutics focuses on developing treatments that address underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The company’s REZPEG (NKTR-358) is positioned as a novel, first-in-class regulatory T cell stimulator.
The market movement suggests investors view Sanofi’s underwhelming results as potentially beneficial for Nektar’s competitive positioning in the atopic dermatitis treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.